Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ: RPRX )

33.38 -0.31 (-0.92%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,600,530
Open 33.53
Bid (Size) 33.00 (1)
Ask (Size) 33.70 (2)
Prev. Close 33.69
Today's Range 33.29 - 33.87
52wk Range 24.05 - 34.20
Shares Outstanding 388,132,400
Dividend Yield 2.52%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Peering Into Royalty Pharma's Recent Short Interest
Via Benzinga
Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma
Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to $250 million in R&D funding from Royalty Pharma. 
Via Benzinga

Performance

YTD
+29.43%
+29.43%
1 Month
+5.23%
+5.23%
3 Month
+25.49%
+25.49%
6 Month
+15.86%
+15.86%
1 Year
+6.65%
+6.65%

More News

Read More
Royalty Pharma Announces R&D Funding Collaboration With Biogen
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue Estimates
Via StockStory
US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What's Driving Markets Tuesday?
Via Benzinga
Royalty Pharma Reports Q4 and Full Year 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
Earnings Scheduled For February 11, 2025
Via Benzinga
Royalty Pharma Earnings: What To Look For From RPRX
Via StockStory
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
From Royalty Pharma plc
Via GlobeNewswire
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Via Benzinga
Walgreens Boots Alliance, Aurora Innovation And Delta Air Lines Are Among Top Large Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?
Via Benzinga
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
Via Benzinga
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces Dividend Increase
From Royalty Pharma plc
Via GlobeNewswire
Jim Cramer Likes Walmart, Recommends Buying This 'Very, Very Good' Financial Stock
Via Benzinga
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer
Via The Motley Fool
2 Exceptional Dividend Stocks Near 52-Week Lows You Could Regret Not Buying on the Dips
Via The Motley Fool
3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer
Via The Motley Fool
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
From Royalty Pharma plc
Via GlobeNewswire
3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade
Via The Motley Fool
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
From Royalty Pharma plc
Via GlobeNewswire
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.